MET and neoplasm: Antitumour activity of foretinib in SNU‐1 xenografts can be explained by its inhibitory effect on other oncogenic pathways including VEGFR2, PDGFR‐β, Axl, c‐Kit, Flt‐3 and Tie2 in tumour epithelial cells or a possible c‐Met activity in non‐epithelial tumour stromal cells.